IQVIA Holdings Inc. logo

IQVIA Holdings Inc.

IQV

NYSEHealthcareMedical - Diagnostics & Research

Previous close

$259.82

+$3.77 · +1.47%

Aug 21, 4:00 PM ET

IQV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

90

Deep Value

Momentum

52

Neutral

Sentiment

69

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Ari Bousbib
Listed since
May 9, 2013
Employees
94,000

Market position

Day range

Current $259.82

52-week range

Current $259.82

Open
$256.79
Previous close
$256.05
Volume
1.14M
0.72× average
Average volume
1.58M
Average daily volume
Market cap
42.77B USD
Beta
1.18
Market reference 1
50-day average
$212.96
+22.00% above average
200-day average
$199.52
+30.22% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
52.94B USD
P/E (TTM)
31.96×
P/B (TTM)
7.04×
P/S (TTM)
2.52×
EV / EBITDA
15.28×
Earnings yield
3.51%
Free cash flow yield
5.29%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
26.23%
Operating margin
13.57%
Net margin
8.10%
Return on equity
20.91%
Return on assets
4.54%
Return on invested capital
8.23%

Financial health

Debt / equity
2.63×
Current ratio
0.75×
Altman Z-score
2.18
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends38%27%15%4%Gross margin, FY2021: 33.45%Gross margin, FY2022: 34.89%Gross margin, FY2023: 34.96%Gross margin, FY2024: 34.89%Gross margin, FY2025: 26.28%Operating margin, FY2021: 10.04%Operating margin, FY2022: 12.48%Operating margin, FY2023: 13.19%Operating margin, FY2024: 14.29%Operating margin, FY2025: 14.02%Net margin, FY2021: 6.96%Net margin, FY2022: 7.57%Net margin, FY2023: 9.06%Net margin, FY2024: 8.91%Net margin, FY2025: 8.34%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 33.45%. Gross margin FY2022 34.89%. Gross margin FY2023 34.96%. Gross margin FY2024 34.89%. Gross margin FY2025 26.28%. Operating margin FY2021 10.04%. Operating margin FY2022 12.48%. Operating margin FY2023 13.19%. Operating margin FY2024 14.29%. Operating margin FY2025 14.02%. Net margin FY2021 6.96%. Net margin FY2022 7.57%. Net margin FY2023 9.06%. Net margin FY2024 8.91%. Net margin FY2025 8.34%.

Income trends

Revenue

16.31B USD+5.87%

Operating income

2.29B USD+3.86%

Net income

1.36B USD-0.95%
Income trends across reported periods17.84B USD11.71B USD5.57B USD−568.4M USDRevenue, FY2021: 13.87B USDRevenue, FY2022: 14.41B USDRevenue, FY2023: 14.98B USDRevenue, FY2024: 15.41B USDRevenue, FY2025: 16.31B USDOperating income, FY2021: 1.39B USDOperating income, FY2022: 1.8B USDOperating income, FY2023: 1.98B USDOperating income, FY2024: 2.2B USDOperating income, FY2025: 2.29B USDNet income, FY2021: 966M USDNet income, FY2022: 1.09B USDNet income, FY2023: 1.36B USDNet income, FY2024: 1.37B USDNet income, FY2025: 1.36B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.87B USD. Revenue FY2022 14.41B USD. Revenue FY2023 14.98B USD. Revenue FY2024 15.41B USD. Revenue FY2025 16.31B USD. Operating income FY2021 1.39B USD. Operating income FY2022 1.8B USD. Operating income FY2023 1.98B USD. Operating income FY2024 2.2B USD. Operating income FY2025 2.29B USD. Net income FY2021 966M USD. Net income FY2022 1.09B USD. Net income FY2023 1.36B USD. Net income FY2024 1.37B USD. Net income FY2025 1.36B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.31B USD15.41B USD14.98B USD14.41B USD13.87B USD
Cost of goods sold12.02B USD10.03B USD9.75B USD9.38B USD9.23B USD
Gross profit4.29B USD5.38B USD5.24B USD5.03B USD4.64B USD
Selling, general, and administrative2B USD1.99B USD2.05B USD2.07B USD1.96B USD
Operating expenses2B USD3.17B USD3.26B USD3.23B USD3.25B USD
Interest income45M USD47M USD36M USD13M USD6M USD
Interest expense729M USD670M USD672M USD416M USD375M USD
Depreciation and amortization1.14B USD1.11B USD1.13B USD1.13B USD1.26B USD
Operating income2.29B USD2.2B USD1.98B USD1.8B USD1.39B USD
Net income1.36B USD1.37B USD1.36B USD1.09B USD966M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+1.73%
11 comparable reports
Latest EPS result
3.15
Estimate 3.03 · Beat by 3.96%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.563.22.852.49Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 3.12, estimate 3.11, surprise +0.32%, Beat. Q2 2025, reported May 6, 2025: actual 2.7, estimate 2.63, surprise +2.66%, Beat. Q3 2025, reported Jul 22, 2025: actual 2.81, estimate 2.77, surprise +1.44%, Beat. Q4 2025, reported Oct 28, 2025: actual 3, estimate 2.98, surprise +0.67%, Beat. Q1 2026, reported Feb 5, 2026: actual 3.42, estimate 3.4, surprise +0.59%, Beat. Q2 2026, reported May 5, 2026: actual 2.9, estimate 2.82, surprise +2.84%, Beat. Q3 2026, reported Jul 28, 2026: actual 3.15, estimate 3.03, surprise +3.96%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 3.25, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.54B4.23B3.91B3.6BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 3.96B USD, estimate 3.93B USD, surprise +0.78%, Beat. Q2 2025, reported May 6, 2025: actual 3.83B USD, estimate 3.77B USD, surprise +1.49%, Beat. Q3 2025, reported Jul 22, 2025: actual 4.02B USD, estimate 3.97B USD, surprise +1.19%, Beat. Q4 2025, reported Oct 28, 2025: actual 4.1B USD, estimate 4.08B USD, surprise +0.50%, Beat. Q1 2026, reported Feb 5, 2026: actual 4.36B USD, estimate 4.24B USD, surprise +2.93%, Beat. Q2 2026, reported May 5, 2026: actual 4.15B USD, estimate 4.1B USD, surprise +1.24%, Beat. Q3 2026, reported Jul 28, 2026: actual 4.37B USD, estimate 4.3B USD, surprise +1.53%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 4.36B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$237.38

8.64% downside
Past 12 months12-month forecastHigh $287Average $237.38Low $185

Rating distribution

45 ratings
Strong buy12%
Buy3680%
Hold716%
Sell12%
Strong sell00%

Recent analyst actions

12 institutions
BMO CapitalmaintainOutperform

IQV news

IQV peers

ETFs holding IQV

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research IQV

research.disclaimer